Cargando…

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial

BACKGROUND: Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir resistance if switching occurred with un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ying, Griesel, Rulan, Omar, Zaayid, Simmons, Bryony, Hill, Andrew, van Zyl, Gert, Keene, Claire, Maartens, Gary, Meintjes, Graeme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209436/ https://www.ncbi.nlm.nih.gov/pubmed/36645792 http://dx.doi.org/10.1093/cid/ciad023

Ejemplares similares

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
por: Keene, Claire M, et al.
Publicado: (2023)

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
por: Griesel, Rulan, et al.
Publicado: (2023)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
por: Zhao, Ying, et al.
Publicado: (2021)

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial
por: Griesel, Rulan, et al.
Publicado: (2021)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Abdominal Ultrasound for the Diagnosis of Tuberculosis Among Human Immunodeficiency Virus-Positive Inpatients With World Health Organization Danger Signs
por: Griesel, Rulan, et al.
Publicado: (2019)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy
por: Cohe, Karen, et al.
Publicado: (2019)

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV‐positive individuals
por: Van Hoving, Daniel J, et al.
Publicado: (2019)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial
por: Bevers, Lisanne A H, et al.
Publicado: (2023)

Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication
por: Parienti, Jean-Jacques, et al.
Publicado: (2021)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
por: Santos, José R, et al.
Publicado: (2023)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania
por: Ntamatungiro, Alex J, et al.
Publicado: (2023)

Association of First-Line and Second-Line Antiretroviral Therapy Adherence
por: Ramadhani, Habib O., et al.
Publicado: (2014)

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
por: Llibre, Josep M, et al.
Publicado: (2022)

Platform Trials — Beware the Noncomparable Control Group
por: Dodd, Lori E., et al.
Publicado: (2021)

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
por: Podzamczer, D, et al.
Publicado: (2021)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Loss to Follow-up and Death Among Individuals With Newly Diagnosed Human Immunodeficiency Virus Receiving Dolutegravir-Based First-Line Antiretroviral Treatment in Eastern Ethiopia: Implications for 95% United Nations Targets
por: Gemechu, Abdella, et al.
Publicado: (2023)

Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV
por: Boyles, Tom H., et al.
Publicado: (2018)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial
por: West, Emily, et al.
Publicado: (2023)

Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
por: Simmons, Bryony, et al.
Publicado: (2014)

Antiretroviral Drug Detection in a Community-Randomized Trial of Universal HIV Testing and Treatment: HPTN 071 (PopART)
por: Fogel, Jessica M, et al.
Publicado: (2022)

A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy
por: Presti, Rachel M, et al.
Publicado: (2021)

Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
por: van Beek, Stijn W, et al.
Publicado: (2022)

Low-level viraemia despite emergence of dolutegravir-resistant variants
por: Botha, Johannes C., et al.
Publicado: (2022)

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials
por: Fournier, Anna L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uj6p0p7221mgnl9c8u7s98h4sd